UCLA researchers have identified the regulatory network that controls the transformation of neuronal progenitor cells into movement nerve cells in chicken and mouse embryos. The study adds insight into the development and functioning of spinal movement nerve cells. It also may contribute to the production of stem cell-derived movement nerve…
News
Neuraltus Pharmaceuticals signaled that it was moving toward the analysis stage of a Phase 2 clinical trial of its ALS therapy NP001. The signal was its announcement that it had completed the last patient visit in the study. Neuraltus conducted the trial (NCT02794857) to confirm the results of a…
Neurodegeneration in a subset of amyotrophic lateral sclerosis (ALS) patients is a consequence of abnormal DNA damage responses, a finding that provides new possibilities for therapeutic interventions. About 5 percent of familial amyotrophic lateral sclerosis (fALS), and up to 1 percent of sporadic ALS (sALS), have been linked to mutations in…
The higher the levels of uric acid in the blood of amyotrophic lateral sclerosis (ALS) patients, the lower the risk of death from all causes, a study found. The body produces uric acid when it breaks down purines, which are substances both normally produced and found in certain…
Biogen is acquiring Karyopharm Therapeutics’ KPT-350 and other potential treatments for neurodegenerative diseases such as ALS. “As a global innovative leader in neuroscience that brings world-class capabilities in developing and commercializing products targeting a broad range of neurological conditions, Biogen is well suited to further advance the development of KPT-350,” Michael…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…
Scientists at the University of Edinburgh discovered that the human neuromuscular junction (NMJ) — a cell connection between neurons and muscle that enables motion — is different in size and structure than other mammals, including mice, which are routinely used in research. “Our findings provide unique insights into the…
Arizona State University will soon launch a new biomanufacturing platform to grow human neurons in vitro to develop and test new therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. The effort includes the development of several types of neurons on a large scale to test…
A defense mechanism that uses a protein linked to ALS could be part of the reason why humans live longer than other animals, a study suggests. The research, “Oxidation of SQSTM1/p62 mediates the link between redox state and protein homeostasis,” appeared in Nature Communications. Autophagy is…
An international team has learned how the body activates a protein responsible for limiting muscle growth, a finding that could lead to therapies to improve ALS patients’ muscle function. The protein, called GDF8 or myostatin, determines both the number of muscle fibers the body produces and the fibers’ size. Researchers’…
Recent Posts
- ALS partnership to give 6 patients expanded access to TRE-515
- Frustration mounts when ALS assistive technology isn’t so helpful
- Trial of experimental ALS therapy pridopidine enrolls first participant
- Advocate for ALS patients, including herself, recognized for work
- New book shares personal stories and insights from people living with ALS